Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 7:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 8,579 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Children Clear all
Recruiting Not applicable Interventional Accepts healthy volunteers

School-based Paraeducator Education for Engagement at Recess

NCT06559267
View directory record Official record
Conditions
Autism Spectrum Disorder, Neurodevelopmental Disorders
Interventions
Remaking Recess, TEAM
Behavioral · Other
Lead sponsor
University of Washington
Other
Eligibility
5 Years and older
Enrollment
350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
3
States / cities
Los Angeles, California • Eugene, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 15, 2025 · Synced Oct 22, 2026, 7:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Improving Vaccinations for Young Children (IVY)

NCT04203277
View directory record Official record
Conditions
Vaccination Refusal
Interventions
IVY
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
Not listed
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 22, 2026, 7:55 PM EDT
Completed Phase 2 Interventional Results available

Early Intervention With Fluoxetine in Autism

NCT00183339
View directory record Official record
Conditions
Autistic Disorder
Interventions
Fluoxetine, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
30 Months to 58 Months
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
2
States / cities
New York, New York • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 26, 2014 · Synced Oct 22, 2026, 7:55 PM EDT
Recruiting Phase 1Phase 2 Interventional

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

NCT04851119
View directory record Official record
Conditions
Colorectal Carcinoma, Endometrial Carcinoma, Melanoma, Neuroblastoma, Ovarian Carcinoma, Pancreatic Ductal Adenocarcinoma, Recurrent Desmoid Fibromatosis, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Hepatocellular Carcinoma, Recurrent Malignant Solid Neoplasm, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Refractory Desmoid Fibromatosis, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Hepatocellular Carcinoma, Refractory Malignant Solid Neoplasm, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Solid Pseudopapillary Neoplasm of the Pancreas, Wilms Tumor
Interventions
Biospecimen Collection, Dual X-ray Absorptiometry, Tegavivint, X-Ray Imaging
Procedure · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
12 Months to 30 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
21
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 22, 2026, 7:55 PM EDT
Completed Phase 2 Interventional

Effects of CX516 on Functioning in Fragile X Syndrome and Autism

NCT00054730
View directory record Official record
Conditions
Fragile X Syndrome, Autism
Interventions
CX516 (Ampalex®)
Drug
Lead sponsor
RespireRx
Industry
Eligibility
18 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
2
States / cities
Sacramento, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 22, 2026, 7:55 PM EDT
Active, not recruiting Phase 3 Interventional

Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis

NCT04624230
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
tofacitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
2 Years to 17 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
19
States / cities
Los Angeles, California • San Francisco, California • Farmington, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 22, 2026, 7:55 PM EDT
Completed No phase listed Observational

Decreasing Antibiotic Use in Infants With Suspected Ventilator-associated Infection

NCT03041207
View directory record Official record
Conditions
Ventilator Associated Pneumonia, Nosocomial Infections in Children, Microbial Colonization
Interventions
Development and implementation of an antibiotic guideline
Behavioral
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
Up to 3 Years
Enrollment
555 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
22
States / cities
Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2019 · Synced Oct 22, 2026, 7:55 PM EDT
Completed Not applicable Interventional

Organizational Skills Interventions for Children With Attention Deficit Hyperactivity Disorder (ADHD)

NCT01176136
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Homework, Organization, and Planning Skills (HOPS) Intervention
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
11 Years to 15 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 30, 2013 · Synced Oct 22, 2026, 7:55 PM EDT
Completed Phase 2 Interventional Results available

A 12-Week Placebo-Controlled Study to Investigate the Efficacy, Safety, and Tolerability of RO7017773 in Participants Aged 15-45 Years With Autism Spectrum Disorder (ASD)

NCT04299464
View directory record Official record
Conditions
Autism Spectrum Disorder (ASD)
Interventions
Placebo, RO7017773
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
15 Years to 45 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
11
States / cities
Phoenix, Arizona • New Haven, Connecticut • Orlando, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 22, 2026, 7:55 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus

NCT06097299
View directory record Official record
Conditions
Respiratory Syncytial Virus
Interventions
mRNA-1345, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
2 Years to 17 Years
Enrollment
349 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
47
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Banning, California + 41 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 22, 2026, 7:55 PM EDT
Recruiting Phase 3 Interventional

A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)

NCT06401330
View directory record Official record
Conditions
Stage I Mixed Cell Type Kidney Wilms Tumor, Stage II Mixed Cell Type Kidney Wilms Tumor, Stage III Mixed Cell Type Kidney Wilms Tumor, Stage IV Mixed Cell Type Kidney Wilms Tumor
Interventions
Bone Scan, Carboplatin, Computed Tomography, Cyclophosphamide, Dactinomycin, Doxorubicin, Etoposide, Irinotecan, Magnetic Resonance Imaging, Nephrectomy, Patient Observation, Positron Emission Tomography, Ultrasound Imaging, Vincristine, X-Ray Imaging
Procedure · Drug · Biological + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
1,656 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
154
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 129 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 22, 2026, 7:55 PM EDT
Terminated Phase 3 Interventional Results available

Magnetic Resonance Imaging of the Liver in Children 0-2 Months of Age With an Intravenous Injection of Eovist/Primovist Which is a Contrast Agent

NCT02084628
View directory record Official record
Conditions
Magnetic Resonance Imaging
Interventions
Gadoxetate disodium (Eovist/Primovist, BAY86-4873)
Drug
Lead sponsor
Bayer
Industry
Eligibility
Up to 2 Months
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
9
States / cities
Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2016 · Synced Oct 22, 2026, 7:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Treatment Phenotypes for Adolescents With Asthma

NCT04228107
View directory record Official record
Conditions
Asthma in Children, Adherence, Treatment
Interventions
Medication monitoring
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 90 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 22, 2026, 7:55 PM EDT
Terminated Not applicable Interventional Results available

RES Prepared With RECELL® Compared to Conventional Care for Healing of Donor Sites in Ages 1-16 Years

NCT03624192
View directory record Official record
Conditions
Skin; Deformity
Interventions
RECELL® Autologous Cell Harvesting Device, Telfa™ Clear and Xeroform™ dressings
Device · Other
Lead sponsor
Avita Medical
Industry
Eligibility
1 Year to 16 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
7
States / cities
Phoenix, Arizona • Sacramento, California • San Diego, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2024 · Synced Oct 22, 2026, 7:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pacific Kids DASH for Health

NCT00905411
View directory record Official record
Conditions
Overweight, Blood Pressure
Interventions
PacDASH intervention
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
5 Years to 8 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Jun 17, 2013 · Synced Oct 22, 2026, 7:55 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Efficacy of Bitter Blockers on Taste Perception in Children and Adults

NCT01407939
View directory record Official record
Conditions
Healthy
Interventions
Not listed
Lead sponsor
Monell Chemical Senses Center
Other
Eligibility
3 Years and older
Enrollment
215 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 16, 2016 · Synced Oct 22, 2026, 7:55 PM EDT
Completed Not applicable Interventional

Training Educators to Conduct Functional Behavior Assessment Via Telehealth

NCT03079765
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Behavioral skills training, Protocol Only
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Oct 22, 2026, 7:55 PM EDT
Completed Phase 1 Interventional

Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma

NCT00994500
View directory record Official record
Conditions
Childhood Burkitt Lymphoma, Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Germ Cell Tumor, Childhood Central Nervous System Germinoma, Childhood Central Nervous System Mixed Germ Cell Tumor, Childhood Central Nervous System Teratoma, Childhood Central Nervous System Yolk Sac Tumor, Childhood Choroid Plexus Tumor, Childhood Craniopharyngioma, Childhood Diffuse Large Cell Lymphoma, Childhood Immunoblastic Large Cell Lymphoma, Childhood Medulloepithelioma, Childhood Meningioma, Childhood Mixed Glioma, Childhood Nasal Type Extranodal NK/T-cell Lymphoma, Childhood Oligodendroglioma, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Central Nervous System Embryonal Tumor, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Childhood Medulloblastoma, Recurrent Childhood Pineoblastoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Childhood Subependymal Giant Cell Astrocytoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway and Hypothalamic Glioma, Recurrent Childhood Visual Pathway Glioma, Recurrent/Refractory Childhood Hodgkin Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
vorinostat, bortezomib, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 21 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
6
States / cities
Chicago, Illinois • Boston, Massachusetts • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2013 · Synced Oct 22, 2026, 7:55 PM EDT
Completed Phase 1 Interventional

Topotecan, Ifosfamide and Carboplatin in Children and Young Adults With Solid Tumors

NCT00502892
View directory record Official record
Conditions
Solid Tumors
Interventions
Topotecan, Ifosfamide, Carboplatin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 45 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Oct 22, 2026, 7:55 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Trial of Echinacea in Children

NCT00029211
View directory record Official record
Conditions
Common Cold
Interventions
Echinacea
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
2 Years to 11 Years
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2003
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 18, 2006 · Synced Oct 22, 2026, 7:55 PM EDT
Completed Not applicable Interventional Results available

Culturally Modified Family Based Therapy for Haitian Youth in South Florida

NCT03876171
View directory record Official record
Conditions
Problem Behavior
Interventions
Haitian youth family-based intervention study: family functioning, Haitian youth intervention study: youth psychoeducational, Haitian family-based intervention study: psychoeducational, Diversion Programs
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
13 Years to 17 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 14, 2024 · Synced Oct 22, 2026, 7:55 PM EDT
Recruiting Phase 2 Interventional

A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months

NCT07126262
View directory record Official record
Conditions
Hypochondroplasia
Interventions
Vosoritide, Placebo
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
0 Months to 36 Months
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
10
States / cities
Phoenix, Arizona • Los Angeles, California • Oakland, California + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 22, 2026, 7:55 PM EDT
Recruiting Phase 1 Interventional

HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors

NCT03911388
View directory record Official record
Conditions
Neoplasms, Brain, Glioblastoma Multiforme, Glioblastoma of Cerebellum, Neoplasms, Astrocytoma, Astrocytoma, Cerebellar, Neuroectodermal Tumors, Neuroectodermal Tumors, Primitive, Cerebellar PNET, Childhood, Cerebellar Neoplasms, Cerebellar Neoplasms, Primary, Cerebellar Neoplasm, Malignant, Cerebellar Neoplasm Malignant Primary, Neoplasm Metastases, Neoplasm Malignant, Neoplasms, Neuroepithelial, Neoplasms, Germ Cell and Embryonal, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Neoplasms, Nerve Tissue, Central Nervous System Neoplasms, Primary, Central Nervous System Neoplasms, Malignant, Nervous System Neoplasms, Neoplasms by Site, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Medulloblastoma Recurrent, HSV, Virus, Pediatric Brain Tumor, Nervous System Cancer, Primitive Neuroectodermal Tumor (PNET) of Cerebellum
Interventions
G207
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
36 Months to 22 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
3
States / cities
Birmingham, Alabama • St Louis, Missouri • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 22, 2026, 7:55 PM EDT
Completed No phase listed Observational

Use of Surface Electromyography Biofeedback to Improve Reaching in Children With Cerebral Palsy

NCT00473161
View directory record Official record
Conditions
Cerebral Palsy, Weakness, Hypertonia
Interventions
surface EMG biofeedback
Device
Lead sponsor
University of Southern California
Other
Eligibility
1 Month to 21 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 23, 2014 · Synced Oct 22, 2026, 7:55 PM EDT